[{"id":"2e6bf495-dfa3-4ba8-b86c-4970f2d282c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01428973","created_at":"2021-01-18T05:54:04.661Z","updated_at":"2024-07-02T16:35:04.762Z","phase":"Phase 2","brief_title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","source_id_and_acronym":"NCT01428973","lead_sponsor":"University of Liege","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-09"},{"id":"20bb3a60-35cb-4903-9d63-a1cf0ddca8cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01962636","created_at":"2021-01-18T08:55:07.216Z","updated_at":"2024-07-02T16:35:30.509Z","phase":"","brief_title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","source_id_and_acronym":"NCT01962636","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" KMT2A • IKZF1","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-11-03"},{"id":"b77bf75c-b84b-4373-9687-867a97189f17","acronym":"","url":"https://clinicaltrials.gov/study/NCT00003838","created_at":"2021-01-17T22:53:23.367Z","updated_at":"2024-07-02T16:35:36.368Z","phase":"Phase 2","brief_title":"Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","source_id_and_acronym":"NCT00003838","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" MYC • BCL2 • CD34","pipe":" | ","alterations":" MYC translocation","tags":["MYC • BCL2 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 04/15/1999","start_date":" 04/15/1999","primary_txt":" Primary completion: 12/14/2018","primary_completion_date":" 12/14/2018","study_txt":" Completion: 06/18/2020","study_completion_date":" 06/18/2020","last_update_posted":"2023-09-21"},{"id":"51dc3555-e944-4b77-91ac-39cecd6429cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00896493","created_at":"2021-01-18T03:26:13.987Z","updated_at":"2024-07-02T16:35:48.244Z","phase":"Phase 2","brief_title":"Ph II of Non-myeloablative Allogeneic Transplantation Using TLI \u0026 ATG In Patients w/ Cutaneous T Cell Lymphoma","source_id_and_acronym":"NCT00896493","lead_sponsor":"Stanford University","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 11/06/2021","primary_completion_date":" 11/06/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-05-11"},{"id":"e81d8890-a6ca-4086-bdec-ade56b1efd5c","acronym":"BMT CTN 1301","url":"https://clinicaltrials.gov/study/NCT02345850","created_at":"2021-01-18T11:09:23.366Z","updated_at":"2024-07-02T16:35:53.892Z","phase":"Phase 3","brief_title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","source_id_and_acronym":"NCT02345850 - BMT CTN 1301","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" HLA-DRB1 • CD34 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 346","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 10/05/2020","primary_completion_date":" 10/05/2020","study_txt":" Completion: 10/05/2020","study_completion_date":" 10/05/2020","last_update_posted":"2023-03-07"},{"id":"20118668-e81b-4e8a-bc41-ef494fc1c7c2","acronym":"BMTCTN0603","url":"https://clinicaltrials.gov/study/NCT00849147","created_at":"2021-01-18T03:13:56.806Z","updated_at":"2024-07-02T16:35:58.244Z","phase":"Phase 2","brief_title":"Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)","source_id_and_acronym":"NCT00849147 - BMTCTN0603","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 06/01/2011","primary_completion_date":" 06/01/2011","study_txt":" Completion: 11/01/2013","study_completion_date":" 11/01/2013","last_update_posted":"2023-01-04"},{"id":"7ef2e0f3-1263-4490-9b0d-ea0be571f605","acronym":"","url":"https://clinicaltrials.gov/study/NCT00489203","created_at":"2021-01-18T01:44:52.854Z","updated_at":"2025-02-25T16:22:35.314Z","phase":"Phase 2","brief_title":"Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00489203","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2021-02-03"},{"id":"d40d35ff-6123-4d22-bb83-b5ad34453c16","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006451","created_at":"2021-01-17T23:53:49.514Z","updated_at":"2024-07-02T16:36:51.910Z","phase":"Phase 3","brief_title":"Bone Marrow Transplantation in Treating Patients With Leukemia","source_id_and_acronym":"NCT00006451","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • cyclosporine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/1996","start_date":" 04/01/1996","primary_txt":" Primary completion: 11/01/2000","primary_completion_date":" 11/01/2000","study_txt":" Completion: 11/01/2000","study_completion_date":" 11/01/2000","last_update_posted":"2020-01-03"},{"id":"e0b6f777-152e-469e-9104-cd4a9ef97e7c","acronym":"MINI HEME","url":"https://clinicaltrials.gov/study/NCT00636909","created_at":"2022-01-21T21:55:33.847Z","updated_at":"2024-07-02T16:37:23.717Z","phase":"Phase 2","brief_title":"Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders","source_id_and_acronym":"NCT00636909 - MINI HEME","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/01/1999","start_date":" 07/01/1999","primary_txt":" Primary completion: 03/01/2006","primary_completion_date":" 03/01/2006","study_txt":"","study_completion_date":"","last_update_posted":"2017-04-06"},{"id":"ed4f1efe-a30a-43c1-ae96-c92769958d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT00031980","created_at":"2021-01-18T00:00:50.444Z","updated_at":"2024-07-02T16:37:30.820Z","phase":"Phase 2","brief_title":"Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer","source_id_and_acronym":"NCT00031980","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclosporine"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2002","start_date":" 03/01/2002","primary_txt":" Primary completion: 05/01/2005","primary_completion_date":" 05/01/2005","study_txt":" Completion: 05/01/2005","study_completion_date":" 05/01/2005","last_update_posted":"2016-07-06"}]